Log in

NASDAQ:MEDPMedpace Stock Price, Forecast & News

$126.95
-1.32 (-1.03 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$126.19
Now: $126.95
$129.27
50-Day Range
$87.73
MA: $107.21
$128.07
52-Week Range
$58.72
Now: $126.95
$144.49
Volume196,772 shs
Average Volume317,375 shs
Market Capitalization$4.50 billion
P/E Ratio45.18
Dividend YieldN/A
Beta1.32
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Read More
Medpace logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860.97 million
Cash Flow$3.86 per share
Book Value$20.16 per share

Profitability

Net Income$100.44 million

Miscellaneous

Employees3,500
Market Cap$4.50 billion
Next Earnings Date10/26/2020 (Estimated)
OptionableOptionable
$126.95
-1.32 (-1.03 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medpace (NASDAQ:MEDP) Frequently Asked Questions

How has Medpace's stock been impacted by COVID-19 (Coronavirus)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 51.8% and is now trading at $126.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Medpace?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medpace
.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Medpace
.

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) posted its earnings results on Monday, July, 27th. The company reported $0.68 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.40 by $0.28. The business earned $205 million during the quarter, compared to analysts' expectations of $181.17 million. Medpace had a return on equity of 16.05% and a net margin of 12.11%. Medpace's quarterly revenue was down 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 earnings per share.
View Medpace's earnings history
.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY20 earnings guidance on Monday, July, 27th. The company provided earnings per share (EPS) guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.33. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $831.87 million.

What price target have analysts set for MEDP?

5 equities research analysts have issued twelve-month price targets for Medpace's shares. Their forecasts range from $75.00 to $124.00. On average, they anticipate Medpace's stock price to reach $97.67 in the next twelve months. This suggests that the stock has a possible downside of 23.1%.
View analysts' price targets for Medpace
.

Has Medpace been receiving favorable news coverage?

Media coverage about MEDP stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Medpace
.

Are investors shorting Medpace?

Medpace saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,580,000 shares, a drop of 10.7% from the April 30th total of 2,890,000 shares. Based on an average trading volume of 387,100 shares, the short-interest ratio is currently 6.7 days. Currently, 9.8% of the company's shares are short sold.
View Medpace's Short Interest
.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Cisco Systems (CSCO), Intuitive Surgical (ISRG) and Trade Desk (TTD).

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.26%), Wasatch Advisors Inc. (7.23%), Pendal Group Ltd (3.04%), Boston Trust Walden Corp (1.11%), Fisher Asset Management LLC (1.01%) and Goldman Sachs Group Inc. (0.91%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace
.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Vanguard Group Inc., Federated Hermes Inc., MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Glenmede Trust Co. NA, Russell Investments Group Ltd., and Goldman Sachs Group Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace
.

Which major investors are buying Medpace stock?

MEDP stock was acquired by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Wasatch Advisors Inc., Redwood Investments LLC, Nordea Investment Management AB, American Capital Management Inc., ClariVest Asset Management LLC, Raymond James & Associates, and Tudor Investment Corp Et Al.
View insider buying and selling activity for Medpace
.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $126.95.

How big of a company is Medpace?

Medpace has a market capitalization of $4.50 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.